Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid FinancialsTipRanks Financial Blog • about 1 month ago
Maxim Group analyst Jason McCarthy has reiterated their bullish stance on CLRB stock, giving a Buy rating today. Jason McCarthy has given his Buy r...
Share to Feed
Related Stocks: NAS:CLRB...
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript March 27, 2024
Cellectar Biosciences, Inc. isnt one of the 30 most popular stocks among hedge funds at the end of the...
Management to host a conference call today at 8:30 am ETFLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical...
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript...
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript...
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of clinical activity achieved 67% Overall Survival and 42% Progression Free...
FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...